Schering Intron A/Rebetol Treatment-Naive Hepatitis C Data Close To Filing
Data from naive chronic hepatitis C patients treated with Schering-Plough's Intron A/Rebetol combination therapy are being analyzed, Schering Hepatology Clinical Director Janice Albrecht, MD, told FDA's Antiviral Drugs Advisory Committee May 4.
You may also be interested in...
Bristol-Myers Squibb's submission of two separate NDAs for the combination use of UFT and leucovorin appears to be a new filing and approval strategy for the development of bundled multi-ingredient products.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011